Silexion Reports Positive SIL204 Uptake Data in KRAS-Driven Cancers; Shares SLXN in Focus

Silexion Therapeutics Corp. (SLXN) on September 28, 2026 reported positive findings from an ongoing translational study of SIL204, its lead RNA interference candidate for KRAS-driven cancers, indicating systemic cellular uptake and gene-silencing activity. The study evaluated the mechanism by which SIL204 is taken up by cells and suppresses target gene expression. KRAS-driven cancers, including pancreatic and colorectal tumors, are among the most difficult to treat and carry limited therapeutic options. The company said the data support continued development of the candidate. No financial terms or timelines for further trials were disclosed. Silexion did not release specific quantitative results from the study.